CANTARGIA AB
556791-6019ActiveDeveloping antibody-based drugs targeting IL1RAP for serious diseases.
Biotechnology Companycantargia.com
Oversikt
- 20–49
- Ansatte
- ≤1t SEK
- Omsetning
- 2009
- Grunnlagt
Nøkkelbeslutningstakere
Hilde H. Steineger
CEO
@cantargia.com+46462XXXXXX
Wolfram Dempke
Chief Medical Officer
@cantargia.com
Magnus Persson
Chairman of the Board
@cantargia.com
Damian Marron
Board Member
@cantargia.com
+6 flere kontakter i Funnelfeedr
Beskrivelse
Cantargia is a biotechnology company focused on developing innovative antibody-based therapeutics. Their primary scientific target is the protein IL1RAP, which plays a role in several serious conditions. The company's mission is to create treatments for cancer as well as autoimmune and inflammatory...
Nanohumps Biosciences Oy